replies: In 1956, when I started my medical education in Aarhus, Denmark, the University was only 20 years old, and we had the opportunity to meet young researchers with fresh attitudes and minds open to new ideas in comparison with the established faculty at the University in Copenhagen, which was almost 500 years old and carried the burden of years of tradition. I was lucky to have a young lecturer in physiology, Jens Christian Schou, who was later awarded the Nobel Prize in Medicine 1997 for his discovery of the enzyme Na + K + ATPase. I was particularly interested in the Krebs cycle and understood that if not enough energy was produced aerobically, then cardiac contractility would be impaired.
How did your early work in acute myocardial infarction inform your eventual thinking on β-blockers for chronic heart failure?
I observed that many of the patients with AMI and agonizing chest pain had both elevated blood pressures and heart rates and thought that reducing heart rate with a β-blocker might be a good idea to try and restore the compromised energy balance in the ischemic myocardium and to help reverse the ongoing necrotic process. At the same time in the laboratory of my supervisor, Åke Hjalmarson, studies were being conducted in isolated perfused rat hearts. When severe ischemia was induced by applying a snare to the left anterior descending coronary artery, it was noticed that very large amounts of catecholamines were released in the perfusate. Therefore, we thought patients with AMI could also have a marked release of catecholamines and that it might be worthwhile to block the overshoot.
You started testing your theory on individual patients yourself. Describe how you did this and the reaction of your supervisors.
While I was working in this primitive CCU in the evenings, I administered cardioselective β-blockers to several patients in pain with large transmural infarcts. Some patients had clinical signs of congestive heart failure with basal lung rales, and I also noted there was no worsening of rales (which in any event could easily be treated with intravenous furosemide). The responses from my superiors the day after my nocturnal patient treatment exercises were not positive. In fact, I was banned from the unit because I had risked the life of the patients by using an unauthorized treatment. The nurses supported me because they had seen the patients improve. I was told I could not stay working in cardiology if I continued these activities, and, because I did not stop, I was eventually transferred to another ward.
I started to work in the General Medicine Ward run by Professor Lars Werkö, and he supported this new idea for treatment (or at least gave me the benefit of the doubt). We continued administering β-blockers to patients arriving at the emergency department with ongoing severe chest pain and signs of transmural infarction. We compared 3 different β-selective blockers with saline and morphine and noticed that neither saline nor morphine had any effect on reducing the sum of the ST elevations in comparison with the β-blockers, and the effect on chest pain was almost as good with β-blockers as the effect of morphine-like drugs. These early observations were published in minor local Scandinavian journals and are almost forgotten today.
Our first article published in the British Heart Journal 1,2 remained unnoticed because of the title, but measurement of noninvasive indices of contractility revealed shortened systolic time intervals and higher systolic blood pressure and heart rates in control patients, suggesting inappropriate increases in sympathetic activity that subsided over the next 5 to 7 days. A single dose of intravenous practolol (18.2 mg) given on the first day of AMI reduced chest pain and the summed STelevation scores in the precordial chest leads in patients with anterior myocardial infarctions.
Our collective efforts led to randomized studies showing a significant reduction in mortality in AMI with early intravenous β-blockers provided that the strict exclusion criteria were applied. Unfortunately a very big randomized study with intravenous β-blockers given to patients with AMI in China did not confirm that β-blockers reduced mortality. The investigators did not apply the strict exclusion criteria as we had in our randomized Swedish trial. It would be interesting to reanalyze the data in the Chinese trial excluding the patients with severe heart failure with widespread rales and signs of imminent shock, because pretreating AMI patients with intravenous β-blockade before PCI or thrombolysis might spare myocardium. Now, we are in a limbo because of the Chinese trial.
In summary, an ischemic myocardium can only perform a sustained mechanical output for a limited period of time before the myocardium succumbs. This could be the same whether we are talking about acute ischemia as in ongoing AMI or in chronic heart failure, which could be a mix of subendocardial ischemia and hibernation, which both could possibly be helped. The next step toward using β-blockers for chronic use was an observation in the middle of the night, when a patient with chronic heart failure presumably attributable to either dilated or ischemic cardiomyopathy (we had no angiographic data) arrived with acute pulmonary edema. I could not improve this with oxygen, morphine, massive doses of furosemide, and rotating tourniquets on his arms and legs (to reduce preload). I had to consider venesection but abstained. At that time, these treatments were the most we could conventionally provide. I noticed the patient had sinus tachycardia of 120 bpm and I thought again that, because I was going to lose the patient, why not try to reduce heart rate with a β-1 selective blocker. With repeated, small, intravenous doses, the heart rate dropped to 70 bpm, there was almost immediate relief of the pulmonary edema and the patient started to urinate. The patient survived the night.
We then started to study patients with DCM. Why? There were 2 reasons. First, there was an interest in patients with DCM at the Sahlgrenska Hospital, and we got a number of referrals. Second, we thought at that time we might be more likely to achieve recovery of a dilated heart without signs of regional necrosis, such as seen in patients with heart failure post-AMI.
We submitted a case report to the British Heart Journal of 7 patients with congestive cardiomyopathy who, in addition to conventional treatment with digitalis and diuretics, were given β-adrenergic receptor blockade for an average of 5.4 months.
I think the cover letter from Professor Lars Werkö, a prominent specialist in internal medicine and cardiology, helped me get the controversial article published. He felt obliged to begin with the words "This man is not completely insane." Our article demonstrated an improvement in the clinical condition of patients with congestive cardiomyopathy shortly after administration of the β-blockers and subsequently an increase in physical working capacity and a reduction of heart size. Noninvasive investigations including phonocardiograms, apex cardiograms, and echocardiograms showed improved ventricular function in all cases. The article was finally accepted after a long correspondence. 3 See the reply from the Editor, Dr. Walter Somerville, in 1975 ( Figure 1) . He was more impressed that there was no deterioration in these patients after β-blockade and wondered if their recovery was because of spontaneous improvement.
Your findings produced a storm of criticism for you and your colleagues, which continued for about a decade, especially in the United Kingdom. Could you describe this time and how it affected your professional and personal life?
Subsequently, professors wrote editorials in the Lancet about "the perverse Swedish cardiologist" who gives β-blockers to patients with heart failure and risks taking their lives. And these were strong people with a great deal of influence. So, at that time, it was going to be a long walk uphill with no external funding and a great deal of skepticism, not only among cardiologists abroad, but also among colleagues in our hospital.
Fortunately, I was not present in the lecture halls in London when professors from the podium declared that it should be absolutely forbidden to give β-blockers to patients with heart failure as those crazy cardiologists in Sweden prescribe. It was extremely important to slowly increase the dose of β-blockers over several weeks. If you give a patient with CHF a high dose of β-blocker from the beginning it may well kill him.
I do not think the controversy affected my professional life directly. I was just a clinical cardiologist with many tasks and I could continue with that. However, it was extremely difficult to get external funding, in particular, from industry which feared that risky studies using β-blockers in CHF could damage the reputation of their use in hypertension and in patients post-myocardial infarction.
A question, which I have often been asked: "Did you sometimes have doubts about the issue?" Yes, of course I had doubts, but once I met the patients again after 6 to 12 months and saw they had clinically improved, my doubts disappeared. I had the strong feeling that there was a rationale for the improvement and over the years we spent a lot of effort trying to explain the mechanisms for this.
After the publication of this article I was welcomed back to the Department of Cardiology and offered a position as Director of a modern CCU with resources for cardiac catheterization and I was also appointed as Co-Director of the hemodynamic laboratory. Doubt and skepticism remained. First, we have to remember that inotropic drugs were being evaluated for use in patients with AMI and heart failure or cardiogenic shock, supported by the pharmaceutical lobbying and influential researchers at Harvard. Second, we had the fact that a number of DCMs recover spontaneously. The problem with β-blockers is that it takes 3 to 12 months before you can record hemodynamic improvement. The benefit with inotropes is an immediate improvement but, unfortunately, long-term deleterious effects. The next problem we faced was the rise of ACE inhibitors, which immediately placed β-blockers in the shadow. So there was an almost 25-year delay before the acceptance of β-blockers as a treatment for heart failure. It seems like the cardiology community can only concentrate on 1 thing at a time.
A very important message from our first article in the British Heart Journal was the very slow onset of improve- ment of contractile variables such as ejection fraction measured with M-mode echocardiography, whereas improvement of heart failure symptoms was fast. I used to say that we were lucky not to be able to perform hemodynamic measurements in these early patients before, and immediately after, starting β-blockade. The negative inotropic findings, such as a fall in cardiac index and a drop in blood pressure, as we, and others, saw later, may have killed the β-blocker concept right from the beginning. Therefore, seen retrospectively, it is easy to understand the sound skepticism in the mid-1970s.
Your next important contribution was a study published in Circulation in 1989 where, in patients with dilated cardiomyopathy, you demonstrated the effects of short-and long-term metoprolol treatment followed by withdrawal, and readministration of this therapy. This was a bold study design with, in my opinion, a "tipping point" conclusion. Could you describe this?
I agree with you that the tipping point may have been the Circulation article from 1989. 4 We were unable to get funding for a large, controlled study, so we decided to give β-blockers to try and demonstrate improvement in patients with DCM and then stop β-blockers and see if they got worse, and then reintroduce them again and see if improvement would occur (Figure 2 ). Of course this was risky, but it was necessary to convince the world that recovery was because of β-blockers and not spontaneous recovery from DCM. We decided to follow the patients up to 1 year after withdrawal of β-blockers to monitor clinical deterioration or at least deterioration of hemodynamic variables in all patients.
Unfortunately, we lost a few patients during the withdrawal phase, but that was foreseen by us and the ethical committee because a few of the patients were in NYHA class IV before the start of treatment and improved only to NYHA class III after β-blocker treatment. Obviously, these patients had a higher risk of deterioration after withdrawal of therapy.
This article awakened interest first among cardiologists from Stanford and Utah, who supported us immensely and together we brought together an underfunded, unsponsored study and completed the Metoprolol in Dilated Cardiomyopathy (MDC) trial published 1993 in Lancet. 5 My American friends used to say that the lack of sponsors forced them to use money meant for different purposes. As a naïve director of other trials, I used to say that the bumble bee did not know that it was not shaped for flying, but it managed to fly anyway. The MDC trial would be underpowered to show an effect on mortality alone. We therefore used the combined effect on morbidity and mortality as our end point, which to our knowledge was the first heart failure trial with such a design. The MDC trial demonstrated that, in patients with idiopathic dilated cardiomyopathy, treatment with metoprolol prevented clinical deterioration, improved symptoms and cardiac function, and was well tolerated.
After these 2 publications, the industry understood that there was something to invest in, and, shortly thereafter, millions of dollars were invested in 3 major placebo controlled trials Eventually, your therapeutic findings were validated and accepted and are now considered "standard of care." I would like you to reflect on "lessons learned" and the path you took.
One of the immediate effects of the MDC trial, which was criticized for not having any impact on mortality, was the fact that the need for heart transplantation was markedly reduced in patients treated with β-blockers and resulted in a recommendation among American transplant cardiologists that patients should never be put on a cardiac transplant list unless they had failed to improve on a β-blocker. Now, no new heart failure treatment trial allows inclusion of patients who have not been challenged by a β-blocker. My biggest concern is that intravenous β-blockade in AMI and unstable angina is not standard treatment because of the fear that some patients may be harmed. Common sense should be applied so we do not give intravenous β-blockade to obvious high-risk patients with ongoing severe left-sided heart failure, preshock, or advanced AV block. By better using the narrow window of opportunity, I believe we could save more myocardium during the delay phase before PCI or thrombolysis. Spared myocardium in the early phase of AMI should therefore lead to fewer patients with heart failure in the future.
Our early assumptions that AMI and chronic heart failure have an energy imbalance problem has been confirmed by us and others and also demonstrated in a chronic heart failure model using MR spectroscopy. Acute heart failure both in an ongoing AMI and in chronic heart failure show a shift in aerobic metabolism to anaerobic metabolism with the production of lactate and fewer ATP molecules. In patients with DCM, maximal contractile force is achieved ≈70 bpm and is weakened as the pacing rate is increased above that level in contrast to normal tissue with maximal force developed at a much higher rate. The effect of β-blockers is very complex. They might achieve some degree of improvement without affecting heart rate such as in patients with sick sinus node or AV block, although this has not been studied in a randomized trial. β-Blockers may also affect renin release by blocking efferent sympathetic nerves to the kidneys and thus, to some degree, affect the RAAS system because they exert an effect on inflammatory cytokines. They could possibly also block the effect of antibodies against the β-1 receptor in DCM.
DISCLOSURES
None.
FOOTNOTES
Circulation is available at http://circ.ahajournals.org.
